| Literature DB >> 23849250 |
Hao Zhang1, Wei Wang, Yao Cheng, Yongchun Song, Kun Zhu, Chengxue Dang.
Abstract
BACKGROUND: The incidence of adenocarcinoma of the esophagogastric junction is increasing. This study aims to evaluate the clinicopathological features of Chinese patients with adenocarcinoma of the esophagogastric junction and to define prognostic factors.Entities:
Mesh:
Year: 2013 PMID: 23849250 PMCID: PMC3720177 DOI: 10.1186/1477-7819-11-155
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Characteristics of patients with adenocarcinoma of the esophagogastric junction
| Age (years) | 65.5±9.7 | 62.4±8.6 | 63.0±8.4 | >0.05 |
| Male:Female | 6:0 | 6.3:1 | 6.1:1 | >0.05 |
| Tumor size (mm) | 35.0±7.7 | 40.8±16.8 | 64.7±27.8 | <0.01 |
| Esophageal invasion (mm) | 28.3±16.3 | 10.7±9.1 | 6.0±7.2 | <0.01 |
| | | | <0.01 | |
| Transhiatal | 2 | 169 | 136 | |
| Transthoracic | 2 | 42 | 17 | |
| Transthoracoabdominal | 2 | 9 | 2 | |
| | | | <0.01 | |
| Total gastrectomy | 0 | 6 | 15 | |
| Proximal gastrectomy | 6 | 214 | 141 | |
| | | | >0.05 | |
| Stage I | 0 | 24 | 9 | |
| Stage II | 1 | 54 | 37 | |
| Stage III | 5 | 142 | 110 | |
| | | | >0.05 | |
| G1/2 | 3 | 115 | 65 | |
| G3/4 | 3 | 105 | 91 | |
| Neoadjuvant chemotherapy | 0 | 11 | 3 | >0.05 |
| Adjuvant chemotherapy | 1 | 40 | 16 | >0.05 |
| | | | >0.05 | |
| Haematogenous | 4 | 57 | 44 | |
| Local recurrence | 1 | 38 | 29 | |
| Nodal recurrence | 1 | 18 | 17 | |
| Peritoneal recurrence | 0 | 2 | 3 |
Figure 1Survival curves of Siewert types. No significant difference in overall survival by subtypes was observed.
Univariate and multivariate predictors of overall survival
| Siewert classification | | | | |
| Type I, II, III | >0.05 | 0.788–1.548 | | |
| Age (years) | | | | |
| <65 or ≥65 | <0.05 | 1.041–2.115 | <0.05 | 1.051–2.206 |
| Gender | | | | |
| Male or Female | >0.05 | 0.628–1.707 | | |
| Tumor maximal size (mm) | | | | |
| <50 or ≥50 | <0.01 | 1.528–3.194 | >0.05 | 0.878–1.920 |
| Esophageal invasion | | | | |
| Positive or Negative | >0.05 | 0.662–1.580 | | |
| T category | | | | |
| T1-2 or T3-4 | <0.01 | 2.085–7.655 | >0.05 | 0.947–6.366 |
| N category | | | | |
| N0, N1, N2, N3 | <0.01 | 1.702–2.401 | <0.01 | 1.611–2.406 |
| Histopathological grade | | | | |
| G1/2 or G3/4 | <0.01 | 1.367–2.416 | >0.05 | 0.909–1.984 |
| Combined organ resection | | | | |
| With or Without | <0.01 | 1.285–3.707 | >0.05 | 0.811–2.410 |
| Lymphovascular invasion | | | | |
| Positive or Negative | <0.05 | 1.117–3.042 | <0.05 | 0.266–0.878 |
| Resection range | | | | |
| Total gastrectomy | | | | |
| Proximal gastrectomy | <0.05 | 1.073–5.013 | >0.05 | 0.512–2.530 |
| Approaches | | | | |
| Transthoracic | | | | |
| Transhiatal | | | | |
| Transthoracoabdominal | >0.05 | 0.740–1.498 | ||
Figure 2Survival curves of lymph node metastasis. There was a significant difference between N categories in patients.
Figure 3Survival curves of lymphovascular invasion. Patients whose lymphovascular invasion was negative had a significantly better 5-year survival rate than those were positive.